Browsing Tag
Jemperli
11 posts
GSK specialty medicines sales rise 15% as £328m restructuring charge weakens reported profit
GSK reported £8.89 billion in third-quarter sales as specialty medicines expanded strongly across HIV, respiratory diseases and oncology. However, vaccines remained weak and a £328 million restructuring charge contributed to lower statutory earnings, while management maintained its 2026 and 2031 growth targets.
GSK Q2 2026 core operating profit rises 7% on specialty medicines strength
GSK Q2 core operating profit rose 7% to £2.8bn, but a £1.3bn camlipixant hit and 2028-2030 dolutegravir cliff frame the £40bn 2031 sales delivery test.
Why AnaptysBio’s new CFO hire may matter more than a routine biotech appointment
AnaptysBio is no longer a classic biotech pipeline bet. Christopher Murphy’s CFO appointment tests whether ANAB can execute as a royalty vehicle.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
Could PP2A-targeted immunotherapy combinations improve outcomes in ovarian clear cell carcinoma?
Could PP2A-targeted immunotherapy reshape ovarian cancer treatment and Lixte’s valuation story? Read the executive analysis on what changes next.
GSK FY2025 results show momentum in HIV and oncology while vaccines and general medicines face pressure
GSK’s FY2025 core EPS grew 12 percent with strong Specialty Medicines performance. Find out how the company is planning to sustain momentum in 2026.
GSK India delivers 32% profit surge—Zejula and Jemperli launches set to transform cancer care
GSK India reports 32% PAT growth in FY25; read how oncology launches and vaccine growth are shaping the company’s future outlook.
GSK Q1 2025 earnings: Specialty medicines power growth as pipeline builds investor confidence
GSK's Q1 2025 earnings beat forecasts on strong Specialty Medicines growth and pipeline strength—read full results, investor sentiment, and stock outlook.
GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab)…
GSK announces significant survival results for Jemperli in endometrial cancer trial
In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has…